Italia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 10-07-2024
- Paid Up Capital ₹ 3.95 M
as on 10-07-2024
- Company Age 28 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.75 Cr
as on 10-07-2024
- Satisfied Charges ₹ 4.00 M
as on 10-07-2024
- Revenue -64.82%
(FY 2023)
- Profit -3274.00%
(FY 2023)
- Ebitda -274.75%
(FY 2023)
- Net Worth -53.51%
(FY 2023)
- Total Assets -71.02%
(FY 2023)
About Italia Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 3.95 M.
The company currently has active open charges totaling ₹5.75 Cr. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Pradeep Mehta and Mukesh Mehta serve as directors at the Company.
- CIN/LLPIN
U24232MP1996PTC010830
- Company No.
010830
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 May 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Italia Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Mehta  | Director | 06-Dec-2022 | Current |
| Mukesh Mehta | Director | 06-Dec-2022 | Current |
Financial Performance of Italia Pharmaceuticals.
Italia Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 64.82% decrease. The company also saw a substantial fall in profitability, with a 3274% decrease in profit. The company's net worth observed a substantial decline by a decrease of 53.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Italia Pharmaceuticals?
Unlock access to Italia Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Bio Medica Laboratories Private LimitedActive 9 years 4 monthsPradeep Mehta and Mukesh Mehta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 24 Feb 2023 | ₹5.00 Cr | Open |
Punjab National Bank Creation Date: 13 Oct 2014 | ₹5.00 M | Open |
M.P. Financial Corporation Creation Date: 08 Mar 1999 | ₹2.50 M | Open |
How Many Employees Work at Italia Pharmaceuticals?
Unlock and access historical data on people associated with Italia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Italia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Italia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
